Compare FRPH & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRPH | ORIC |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | 104 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.3M | 1.3B |
| IPO Year | 1995 | 2020 |
| Metric | FRPH | ORIC |
|---|---|---|
| Price | $21.52 | $12.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 61.6K | ★ 1.4M |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $41,774,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $129.50 | ★ N/A |
| Revenue Growth | ★ 0.65 | N/A |
| 52 Week Low | $20.53 | $3.90 |
| 52 Week High | $29.68 | $14.93 |
| Indicator | FRPH | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 43.22 | 54.67 |
| Support Level | N/A | $11.37 |
| Resistance Level | $24.59 | $13.89 |
| Average True Range (ATR) | 0.74 | 0.80 |
| MACD | -0.12 | -0.11 |
| Stochastic Oscillator | 46.25 | 77.75 |
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.